Felodipin Stada Retard

Felodipin Stada Retard





HK Medical Supplies
Health Express
Full Prescribing Info
One modified release tablet contains 5 mg felodipine.
Pharmacology: Felodipine is a calcium antagonist of the dihydropyridine class of calcium channel blockers. Calcium antagonists interfere with the voltage-dependent L-type (slow) calcium channels in the plasma membranes of smooth muscle cells and reduce the inflow of calcium ions with the result of vasodilation.
Felodipine is a vasoselective calcium antagonist: it has a much greater selectivity for vascular smooth muscle than for myocardial muscle. Felodipine selectively dilates arterioles with no effects on venous vessels. Felodipine leads to a dose-related lowering of blood pressure via a vasodilatation and consequently a reduction of peripheral vascular resistance. It reduces both systolic and diastolic blood pressure. The hemodynamic effect of felodipine is accompanied by reflex (baroreceptor-mediated) tachycardia. In therapeutic doses, felodipine has no direct effect on either cardiac contractility or cardiac conduction. Felodipine reduces renal vascular resistance. The glomerular filtration rate remains unchanged.
Pharmacokinetics: Felodipine is rapidly and completely absorbed following oral administration. Peak plasma levels are reached with the prolonged release formulation after 3-5 hours.
Constant levels are achieved approx. 3 days after starting treatment. Due to an extensive first-pass effect, only approx. 15% of the administered dose is systemically available.
The plasma protein binding of felodipine is > 99%. The volume of distribution is 10 l/kg, so that felodipine is rapidly distributed in extravascular tissue. Felodipine is extensively metabolized in the liver. No unchanged parent substance is detectable in the urine. The inactive hydrophilic metabolites formed by hepatic biotransformation are mainly eliminated renally (to approx. 70%) and the remainder is excreted in the feces. Felodipine is eliminated in several phases. Approximately 50% of the administered dose is excreted with a half-life of 4 hours and the mean terminal half-life is 18 hours. The mean plasma clearances is 1100 ml/l and depends on the hepatic blood flow. Elevated plasma concentrations have been measured in patients with impaired hepatic function and in elderly patients. Renal impairment does not affect the pharmacokinetics of felodipine, although accumulation of inactive metabolites occurs in renal failure.
The bioavailability of felodipine is affected by the simultaneous ingestion of fatty food (increase in plasma level).
Essential hypertension. Angina pectoris.
Dosage/Direction for Use
Unless prescribed otherwise, the following dosage regimen is recommended: Treatment should always be started with 5 mg of Felodipine (equivalent to 1 Felodipin STADA 5 mg retard modified-release tablet) once daily. Dosage may be increased to 10 mg of Felodipine (equivalent to 2 Felodipin STADA 5 mg retard modified-release tablet) once daily. At least 2 weeks should have elapsed before dosage is increased.
The maximum daily dose is 10 mg felodipine.
Elderly patients: Elderly patients in particular are recommended a starting dose of 2.5 mg of felodipine once daily. Lower strengths of this drug are available for this purpose. Dose increase should be made with particular caution.
Patients with liver function impairment: Patients with mild-to-moderate impairment of liver function should start treatment with 2.5 mg of felodipine once daily. Lower strengths of this drug are available for this purpose. Dose increases should be made only after critically weighing the effects and side effects of felodipine.
Method of administration and duration of therapy: The modified-release tablets should be taken in the morning with a sufficient amount of liquid (such as a glass of water, but no grapefruit juice). The modified-release tablets should be swallowed whole and neither chewed nor divided.
The tablets should not be taken with a high-fat meal.
If a dose is missed or less than the prescribed dose is taken, the dose should be taken as soon as remembered and therapy should be continued as prescribed on the following day. Never double the dose to make up for a missed dose. Treatment should not be interrupted or stopped prematurely without consulting the doctor beforehand. Abrupt discontinuation of the drug may produce life-threatening blood pressure increase (hypertensive crisis) in isolated instances.
The duration of therapy will be decided by the treating doctor.
The main manifestation that might be expected is excessive peripheral vasodilatation with marked hypotension and in rare cases bradycardia. The therapeutic measures should include elimination of the active ingredient and reconstitution of stable cardiovascular conditions. If hypotension occurs, symptomatic treatment should be provided; the patient should be placed supine with the legs elevated. In case of accompanying bradycardia, atropine (0.5-1.0 mg) should be given intravenously. Additional fluid administration should only be initiated if under hemodynamic control to avoid cardiac overload. Sympathomimetic drugs with predominant effect on the α1-adrenoreceptor may also be given.
Felodipine is dialysable to a minimal extent (approx. 9%).
Felodipine Stada retard must not be taken by patients with any of the following conditions: hypersensitivity to felodipine or to any of the excipients; stroke within the last six months; cardiovascular shock; valvular heart disease (higher-grade aortic or mitral stenosis); heart muscle disease with narrowing of the cardiac cavity (hypertropic obstructive cardiomyopathy); unstable angina pectoris; acute myocardial infarction (with the last 8 weeks); higher-grade disturbances of impulse conduction from the atria to the ventricles of the heart (second- and third-degree AV block); congestive heart failure; severe impairment of kidney function (renal insufficiency, GFR < 30 ml/min, creatinine > 1.8 mg/dl); severe impairment of liver function; pregnancy.
Special Precautions
Felodipine should be used with caution in patients with: Conduction disorders, heart failure, tachycardia and haemodynamically relevant aortic and/or mitral valve stenosis.
Mild to moderate hepatic impairment, as the anti-hypertensive effect may be enhanced.
If treatment with felodipine is discontinued abruptly, a hypertensive crisis may occur in individual cases.
Effects on ability to drive and use machines: Treatment of essential hypertension with Felodipine Stada retard requires regular medical monitoring. Individually different reactions may alter alertness to such an extent that the ability to actively participate in road traffic, operate machines or work without a firm support is impaired. This applies especially at the start of therapy, when increasing the dose, switching medications or using alcohol at the same time.
Use in children: Felodipine should not be used in children because safety has not been established.
Use In Pregnancy & Lactation
Felodipine is contraindicated during the entire duration of pregnancy, as animal experiments have demonstrated fetal damage.
Pregnancy must be excluded before starting treatment with felodipine.
Felodipine is excreted in breast milk. If the breast-feeding mother is taking therapeutic doses of felodipine, a fully breast-fed infant absorbs only a very low dose of the active substance with the breast milk. There exists no experience concerning the risks for the infant.
Side Effects
Frequently, flushing, headache or tinnitus may occur, particularly at the beginning of treatment, when the dose is increased or when high doses are administered.
Occasionally peripheral edema occurs. Occasionally, particularly at the beginning of treatment, angina pectoris attacks may occur, or in patients with pre-existing angina pectoris there may be an increase in the frequency, duration and severity of the attacks. Myocardial infarction has been reported in isolated cases.
Dizziness, fatigue, hypotension, syncope, palpitations, tachycardia and dyspnea, restlessness, paresthesia, tremors, myalgia, arthralgia, gastro-intestinal complaints (e.g. nausea, vomiting, diarrhoea, constipation), weight gain, sweating, pollakisuria, skin and hypersensitivity reactions such as pruritus, urticaria, and rash have been observed rarely. Very rarely leucocycoclastic vasculitis and photosensitisation have been observed.
Felodipine treatment may lead to gingival hyperplasia and gingivitis in rare cases.
Rarely, a leucocytoblastic vasculitis was observed.
In individual cases, hepatic function disorders (elevated transaminases levels), exfoliative dermatitis, angioedema and fever were observed. In individual cases erection disorders and gynecomastia have been reported.
The doctor or pharmacist should be informed if any adverse effects not described is experienced.
Drug Interactions
The blood pressure lowering effect of Felodipine Stada retard may be increased by other blood pressure lowering drugs and by certain (tricyclic) antidepressants.
The breakdown of felodipine involves a certain enzyme system in the liver (cytochrome P450 3A4). Concurrently administered drugs that interfere with this enzyme system may therefore interact with felodipine to produce: Increased blood levels of Felodipine when medicinal products that contain such drugs as cimetidine, erythromycin, itraconazole or ketoconazole are used at the same time. Grapefruit, which contains enzyme-inhibiting flavonoids, can also increase the plasma level of felodipine.
Reduced blood levels of felodipine when medicinal products that contain such drugs as carbamazepine, phenytoin or barbiturates are used at the same time.
Please bear in mind that these precautions may also apply to recently used medicines.
Do not store above 25°C.
MIMS Class
Calcium Antagonists
ATC Classification
C08CA02 - felodipine ; Belongs to the class of dihydropyridine derivative selective calcium-channel blockers with mainly vascular effects. Used in the treatment of cardiovascular diseases.
MR tab 5 mg (light pink, round, biconvex coated tablet, with imprint '5' on one side) x 100's.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in